Thermo Fisher ScientificTMORevenue: is the business selling more than it used to?
$44.6B+4% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $44.6B in 2025, compounding -0% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $46.3B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMONet income: how much of that revenue becomes profit?
$6.7B+6% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $6.7B in 2025, compounding -1% a year over three years. Trailing twelve-month profit stands at $7.0B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOHow fast is it growing, year by year?
+3.9%revenue growth, FY 2025
→Revenue grew +4% in 2025 against a five-year average of +7%. Earnings grew faster (+6%), so each new dollar of sales is arriving more profitably.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMORevenue per share: is your slice growing as fast as the company?
$117.87revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-27), not a full fiscal year
→Revenue per share reached $117.87 in 2025, compounding +1% a year against -0% for TMO as a whole. Buybacks added roughly 1.4 points to your per-share result. Free cash flow per share stands at $16.65.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOFree cash flow: what is left in real cash after everything?
$6.3B−13% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $6.3B in 2025, compounding -3% a year since 2022. The trailing twelve months stand at $7.3B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→14 cents of every sales dollar became free cash in 2025, and it has held steady since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-27), not a full fiscal year
→The biggest claim on each sales dollar is capital spending, at 3% of revenue (research and development 3%, stock compensation 1%). That share has fallen since 2022, so the cost of competing is easing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in 3 of the last 5 years, most recently +6% against +4%. Each additional dollar of sales is landing more profitably than the last - the definition of operating leverage.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-27), not a full fiscal year
→Operating margin has held near 17% since 2022. After everything, 15 cents of each sales dollar reaches net profit. TMO doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-27), not a full fiscal year
→ROE of 13% and ROCE of 8% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOWhat has the market paid for TMO over time?
33.2xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 33.2x earnings, the market is paying +11% more than TMO's own 11-year median of 29.8x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOWhat cash return does the business throw off per dollar of market value?
3.2%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 3.2% of annual free cash flow, less than its 11-year median of 3.7% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOCould it handle its debt if things went wrong?
→Debt of $45.7B sits against $4.1B of cash, or 0.9x shareholders' equity. Earnings cover interest 5.5 times - adequate, with less room than it looks in a downturn.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOIs the company's own capital growing?
→The company's own capital grew from $46.7B in 2023 to $52.7B (+13%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOHow much goes back, and how much leaks out as stock comp?
→Shareholders received $3.0B in buybacks and $636M in dividends in 2025. Stock compensation issued $310M of new shares in the same year, offsetting 9% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOHow fast is your ownership being diluted - or concentrated?
→The share count shrank 1.3% in 2025, averaging 1.4% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOIs the dividend cheque growing?
→The dividend per share reached $1.68 in 2025, compounding +15% a year since 2020.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOCan it afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-27), not a full fiscal year
→The dividend consumed 9% of profit and 10% of free cash flow in 2025. That leaves room to keep paying through a weak year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMODoes TMO earn more on its capital than that capital costs?
→TMO earns 8.1% on the capital it employs, below the 10% most investors treat as the cost of capital. It was 10.5% in 2022, so the trend is down, though the path has been bumpy.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOTMO has issued or retired shares - did shareholders end up better off?
→TMO has shrunk its share count -2% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is +292% over the same years.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27
Thermo Fisher ScientificTMOAre the people running it buying or selling?
→Insiders sold $63M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 34 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-27